Idorsia announces
financial results for the
first nine months of 2020
Positive results in second
pivotal study with
daridorexant for
patients with
insomnia
There’s more to Idorsia
than meets the eye!
Read the interview with
our CEO & CSO to get to
the bottom of the story...
Our key assets have
the potential to
transform treatment in
the target indications...
We hope you find everything you need to understand how Idorsia intends to achieve its ambitious goals. If you need any further support please don't hesitate to reach out to us.
Shareprice
Stay informed
Idorsia offers an electronic ‘Stay informed’ service. You will get the news sent to you.
News
| 27 Oct 2020 | |
| 21 Oct 2020 | |
| 20 Oct 2020 | |
| 08 Oct 2020 | |
| 02 Sep 2020 |
Events
| Event | When |
| Bryan Garnier European Healthcare Conference | November 16, 2020 |
| Jefferies London Healthcare Conference | November 17-18, 2020 |
| Credit Suisse Swiss Equity Conference | November 20, 2020 |
| J.P. Morgan Healthcare conference | January 11-12, 2021 |
| BofA Securities SMID Cap Conference | January 12-13, 2021 |
| Baader Helvea Swiss Equities Conference | January 14, 2021 |
| Octavian Seminar Flims | January 14-17, 2021 |
| Full-Year 2020 Financial Results reporting* | February 4, 2021 |
| First Quarter 2021 Financial Results reporting* | April 22, 2021 |
| Annual General Meeting of Shareholders | May 12, 2021 |
| Half-Year 2021 Financial Results reporting* | July 27, 2021 |
*We will be in a silent period for 10 days ahead of the financial reporting.
Financial information
The company reports on its financial performance on a quarterly basis starting its financial year on January 01. Read all the latest financial information from Idorsia, including our financial guidance and how the company is funded.
Our strategy
Find out more about the key priorities that management has set in order to develop Idorsia into one of Europe’s leading biopharmaceutical company.
Development pipeline
Idorsia has a diversified clinical development pipeline in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders, and orphan diseases.
Corporate reports
The company publishes a Half Year and Annual Report report summarizing its operational and financial performance, starting its financial year on January 01.
Stock information
The registered shares of Idorsia Ltd were listed on the SIX Swiss Exchange on June 16, 2017 (symbol: IDIA). Get all the latest information about our stock, interact with charting tools, and see what the covering analysts think about the company's future performance.
Contact
Andrew C. Weiss
Senior Vice President, Head of Investor Relations and Corporate Communications